Guillain-Barre Syndrome
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Shield TherapeuticsMA - Wellesley
1 programSafety Study of GBS Following Menactra Meningococcal VaccinationN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
argenxEfgartigimod Alfa-Fcab
Shield TherapeuticsSafety Study of GBS Following Menactra Meningococcal Vaccination
Clinical Trials (2)
Total enrollment: 6,000,000 patients across 2 trials
Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome
Start: Sep 2024Est. completion: Feb 20260
Phase 2Withdrawn
Safety Study of GBS Following Menactra Meningococcal Vaccination
Start: Mar 2005Est. completion: Dec 20106,000,000 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.